Key result
Streptozotocin-induced diabetes is linked to reduced pancreatic ACE and AT1 receptor expression in rats.
Why the study?
The renin-angiotensin system is altered in diabetes, but changes in angiotensin II receptor AT1 and ACE mRNA expression in the pancreas in vivo were not fully characterized.
Answers are grounded in this paper and cite their sources.
Streptozotocin-induced diabetes in rats is associated with down-regulation of the pancreatic renin-angiotensin system during the early stage of diabetes development.
The renin-angiotensin system (RAS) is altered in diabetes. The aim of our study was to investigate whether streptozotocin-induced diabetes was associated with a change in angiotensin II receptors AT (1) and angiotensin-converting enzyme (ACE) mRNA expression in the pancreas in vivo. Rats were synchronized to a 12:12 light:dark cycle. Pancreas tissue sampling was done at 4 h intervals during 24 h cycle starting 17 days after streptozotocin (STZ) treatment (65 mg/kg of body weight). Real time PCR showed decreased expression of ACE in the pancreas after STZ administration during the dark phase. Expression of AT (1) was decreased in diabetic rats during the light and the dark phase of 24 h cycle. Our data show down-regulation of the pancreatic RAS during early stage of diabetes development.
No takes yet. Share an insight, caveat, or question.
Monošíková et al. (2009) studied Streptozotocin-induced diabetes. Streptozotocin-induced diabetes vs. Non-diabetic rats was evaluated on Expression of angiotensin II receptors AT(1) and ACE mRNA in the pancreas. Streptozotocin-induced diabetes in rats was associated with decreased expression of ACE during the dark phase and decreased AT1 expression during both light and dark phases in the pancreas.
Synapse has enriched 10 related papers. Consider them for comparative context: